NTRK2 and neuroblastoma: In vivo growth inhibition and substantially reduced phosphorylation in TrkB-expressing NB xenografts were also observed after treatment as a single agent or in combination with irinotecan or temozolomide (TMZ), eliciting increased EFS when compared to controls [730].